Jiangsu (SH:688426)2025-02-27 07:50Financial Performance - Total revenue for 2024 was CNY 128.25 million, a decrease of 25.15% compared to the previous year[3] - Net profit attributable to the parent company was CNY -162.49 million, down 92.50% year-on-year[3] - Basic earnings per share were CNY -1.46, a decrease of 94.67% compared to the previous year[3] - Operating profit fell by 70.56% year-on-year, totaling CNY -168.95 million[10] - The net profit excluding non-recurring gains and losses was CNY -185.66 million, a decrease of 55.37% year-on-year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 1,614.65 million, a decline of 11.39% from the beginning of the period[6] - The company's equity attributable to the parent company decreased by 12.17% to CNY 1,461.13 million[6] Market and Operational Challenges - The decline in revenue was attributed to price competition and the ongoing market promotion of new products and technologies[7] - Increased R&D investments and marketing expenditures contributed to the rise in operating expenses during the reporting period[8] Strategic Initiatives - The company is actively expanding its presence in the fields of fourth-generation sequencing, gene synthesis, and diagnostic reagents[8]